�QuatRx Pharmaceuticals, a
privately-held biopharmaceutical company focused on development and
commercialization of compounds to treat internal secretion, metabolic and
cardiovascular disorders, announced that it has initiated a second
Phase 3 clinical trial of Ophena(TM) (ospemifene tablets), the company's
estrogen-free oral therapy in exploitation for the treatment of vaginal
symptoms associated with menopause.
The study is the instant pivotal Phase 3 clinical trial for Ophena(TM),
a new selective estrogen sensory receptor modulator (SERM) for the treatment of
postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal
women. PVS, too known as vaginal atrophy, is characterized by progressive
long-term vaginal symptoms such as waterlessness, irritation and sexual pain
(dyspareunia). The first Phase 3 tribulation for Ophena(TM) met all the
co-primary endpoints at a 60 mg dose, with statistically significant
improvements in vaginal dryness and dyspareunia, as well as statistically
meaning improvement in the proportion of parabasal and superficial
cells in the epithelial tissue of vaginal walls and a decline in vaginal pH
levels.
The randomised, double-blind study will search to recruit 750
postmenopausal women at more than 100 trial centers throughout the United
States. Women participating in the study will be treated with either a 60
mg once everyday oral lucy in the sky with diamonds of Ophena(TM) or placebo over the 12-week intervention
period. All women testament also be supplied with a non-hormonal vaginal
lubricating substance to be applied as needed during the treatment period.
The co-primary endpoints of the study ar the change from baseline to
week 12 in the per centum of parabasal cells in the vaginal maturation
index, the percentage of superficial cells in the vaginal maturation index,
vaginal pH, and improvements in the most irritating moderate to severe
vulvovaginal atrophy symptoms of vaginal dryness and dyspareunia.
"We were identical pleased with the results of the first Phase 3 trial for
Ophena(TM) and conceive this following pivotal study will typify another
important development milestone for QuatRx," said Robert L. Zerbe, M.D.,
head executive officer and president of QuatRx. "For the large population
of postmenopausal women affected by progressive and pestiferous vaginal
symptoms, and specially those implicated about the health risks associated
with long-term estrogen-based therapy, we believe Ophena(TM) has the
potential to be an important new treatment option."
About Postmenopausal Vaginal Syndrome
Postmenopausal vaginal syndrome (PVS) is a inveterate and progressive
condition characterized by symptoms including vaginal dryness, sexual pain
(dyspareunia) and botheration. Declining oestrogen levels during menopause
can buoy cause tissues of the vaginal facing to mature thinner and to miss
elasticity, a condition known as withering. Dryness and irritation associated
with reductions in vaginal secretions oft cause pain sensation or hemorrhage during
sexual intercourse. It is estimated that 45-75 percent of post-menopausal
women experience inveterate symptoms of PVS. Current prescription treatments
approved for this circumstance all bear estrogen, administered either
orally or locally in the vagina. SERMs that ar currently approved and
marketed in the United States have non been shown to have beneficial
effects on vaginal tissue and none are approved for use in treating
symptoms of PVS.
About QuatRx
QuatRx Pharmaceuticals is focused on the discovery, licensing,
evolution and commercialization of compounds in the endocrine, metabolous
and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has
three other product candidates in active clinical development and an
advanced presymptomatic program. Fispemifene is a new selective estrogen
sensory receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective
thyroid receptor beta agonist, is in Phase 1 as a potency treatment for
dyslipidemia. Becocalcidiol, a novel Vitamin D analogue, is in Phase 2
clinical trials for the treatment of psoriasis through QuatRx's partner,
Galderma. QuatRx's presymptomatic program is designed to address sex steroid
dependent diseases through inhibition of 17beta-HSD enzymes. In Europe,
QuatRx operates through its Finnish subsidiary company, Hormos Medical Ltd, placed
in Turku, Finland. For press releases and other Company info, please
chaffer http://www.quatrx.com.
QuatRx Pharmaceuticals
http://www.quatrx.com
More info
Wednesday 10 September 2008
Sunday 31 August 2008
Zoledronic Acid Improves Bone-Mineral Density Loss In Premenopausal Patients Using Endocrine Therapies For Early Stage Breast Cancer
�
When at the same time administered, zoledronic acid partnered with
accessory endocrine therapy prevents pearl loss in women with breast
cancer, and improved bone-mineral tightness after handling, according to
an clause released on August 20, 2008 in The Lancet Oncology.�
For patients with early breast crab, endocrine therapy is used
routinely spell the tumors may inactive respond. One serious side effect
in premenopausal women on this treatment is bone loss, which has
received serious attention from clinicians. To quantify how endocrine
therapy affects bone-mineral density in the presence of co-occurrence
zoledronic acidulent, Professor Michael Gnant of the Medical University of
Vienna, General Hospital of Vienna, and colleagues performed a
prospective work of patients included in the�Austrian Breast
and Colorectal Cancer Study Group trial-12 (ABCSG-12.)
In this run, premenopausal women were randomised to have one of
two hormone therapies, either 3 years of goserelin plus tamoxifen or
goserelin plus anastrozole. Each of these groups were randomised to
receive concomitant zoledronic acid or without, making a tot up of four
subgroups. A total 404 women were included in this substudy, of whom
199 were assigned to endocrine therapy only, and 205 were assigned the
endocrine therapy with zoledronic acid. The women were evaluated for
lumbar-spine and trochanter bone-mineral density
using�dual-energy X-ray absorptiometry. Measurements were
taken at 0, 6, 12, 36, and 60 months, and the primary evaluated point
was the bone mineral density after one twelvemonth.
Patients world Health Organization were only administered hormone therapy had significant
bone-mineral density loss in comparability with their baseline evaluations
after 3 years. After 5 age, when the therapy regime had been
completed for 2 eld, some bone-mineral density recuperation was noted,
but non back to baseline levels. The patients on the concomitant
therapies, in contrast, remained unchanging with baseline values at 3
age, and had increased denseness after 5 years.
In conclusion, the authors note that victimization zoledronic acerbic in
combination with turn endocrine therapy in premenopausal,
early-stage breast cancer patients can potentially maintain their
bone-mineral tightness through this therapy and possibly meliorate bone
mineral density by and by. "The findings presented here offer important
information related to to os health for premenopausal women undergoing
adjuvant endocrine therapy," Notes Prof. Gnant.
Adjuvant endocrine therapy plus zoledronic acid in
premenopausal women with early-stage breast genus Cancer: 5-year review of
the ABCSG-12 bone-mineral density substudy
Michael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth,
Franz Kainberger, Helmut Ka?ssmann, Jutta Claudia Piswanger-Solkner,
Michael Seifert, Ferdinand Ploner, Christian Menzel, Peter Dubsky,
Florian Fitzal, Vesna Bjelic-Radisic, Gu?nther Steger, Richard Greil,
Christian Marth, Ernst Kubista, Hellmut Samonigg, Peter Wohlmuth,
Martina Mittlbock, Raimund Jakesz, on behalf of the Austrian Breast and
Colorectal Cancer Study Group (ABCSG)
Lancet Oncol 2008; 9: 840-49
DOI:10.1016/S1470-2045(08)70204-3
Click Here For Journal
Written by Anna Sophia McKenney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More information
When at the same time administered, zoledronic acid partnered with
accessory endocrine therapy prevents pearl loss in women with breast
cancer, and improved bone-mineral tightness after handling, according to
an clause released on August 20, 2008 in The Lancet Oncology.�
For patients with early breast crab, endocrine therapy is used
routinely spell the tumors may inactive respond. One serious side effect
in premenopausal women on this treatment is bone loss, which has
received serious attention from clinicians. To quantify how endocrine
therapy affects bone-mineral density in the presence of co-occurrence
zoledronic acidulent, Professor Michael Gnant of the Medical University of
Vienna, General Hospital of Vienna, and colleagues performed a
prospective work of patients included in the�Austrian Breast
and Colorectal Cancer Study Group trial-12 (ABCSG-12.)
In this run, premenopausal women were randomised to have one of
two hormone therapies, either 3 years of goserelin plus tamoxifen or
goserelin plus anastrozole. Each of these groups were randomised to
receive concomitant zoledronic acid or without, making a tot up of four
subgroups. A total 404 women were included in this substudy, of whom
199 were assigned to endocrine therapy only, and 205 were assigned the
endocrine therapy with zoledronic acid. The women were evaluated for
lumbar-spine and trochanter bone-mineral density
using�dual-energy X-ray absorptiometry. Measurements were
taken at 0, 6, 12, 36, and 60 months, and the primary evaluated point
was the bone mineral density after one twelvemonth.
Patients world Health Organization were only administered hormone therapy had significant
bone-mineral density loss in comparability with their baseline evaluations
after 3 years. After 5 age, when the therapy regime had been
completed for 2 eld, some bone-mineral density recuperation was noted,
but non back to baseline levels. The patients on the concomitant
therapies, in contrast, remained unchanging with baseline values at 3
age, and had increased denseness after 5 years.
In conclusion, the authors note that victimization zoledronic acerbic in
combination with turn endocrine therapy in premenopausal,
early-stage breast cancer patients can potentially maintain their
bone-mineral tightness through this therapy and possibly meliorate bone
mineral density by and by. "The findings presented here offer important
information related to to os health for premenopausal women undergoing
adjuvant endocrine therapy," Notes Prof. Gnant.
Adjuvant endocrine therapy plus zoledronic acid in
premenopausal women with early-stage breast genus Cancer: 5-year review of
the ABCSG-12 bone-mineral density substudy
Michael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth,
Franz Kainberger, Helmut Ka?ssmann, Jutta Claudia Piswanger-Solkner,
Michael Seifert, Ferdinand Ploner, Christian Menzel, Peter Dubsky,
Florian Fitzal, Vesna Bjelic-Radisic, Gu?nther Steger, Richard Greil,
Christian Marth, Ernst Kubista, Hellmut Samonigg, Peter Wohlmuth,
Martina Mittlbock, Raimund Jakesz, on behalf of the Austrian Breast and
Colorectal Cancer Study Group (ABCSG)
Lancet Oncol 2008; 9: 840-49
DOI:10.1016/S1470-2045(08)70204-3
Click Here For Journal
Written by Anna Sophia McKenney
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More information
Monday 11 August 2008
Moguai
Artist: Moguai
Genre(s):
House
Discography:
Moguai
Year: 2004
Tracks: 2
Live @ Mayday
Year: 2002
Tracks: 1
Wednesday 6 August 2008
Troy Pierce
Artist: Troy Pierce
Genre(s):
Electronic
Techno
Dance
Discography:
Getting Lost EP
Year: 2007
Tracks: 10
Run
Year: 2005
Tracks: 4
Red Velvet Lines Black Box
Year: 2005
Tracks: 3
25 Bitches (Vol. II)
Year: 2005
Tracks: 3
25 Bitches (Vol. I)
Year: 2005
Tracks: 4
Thursday 19 June 2008
Spelling Doctor Plans Jolie Trip
The doctor who delivered Tori Spelling's baby daughter on Monday is set for a busy summer - he's also booked to oversee Angelina Jolie's pregnancy. Dr. Jason Rothbart took charge of Spelling's C-section at Cedars-Sinai Medical Center in Los Angeles, and the obstetrician/gynaecologist is now reportedly planning a trip to France where he'll attend to another second-time mum, Jolie. Rothbart stayed in Namibia with the star to deliver her first biological child, Shiloh, who is now two. Jolie is due to give birth to twins later this summer .
See Also
See Also
Friday 13 June 2008
Toy Dolls
Artist: Toy Dolls
Genre(s):
Punk
Alternative
Rock: Punk-Rock
Discography:
One More Megabyte
Year: 2005
Tracks: 14
Our Last Album?
Year: 2004
Tracks: 16
Ten Years Of Toys
Year: 2002
Tracks: 16
Anniversary Anthems (Japan)
Year: 2000
Tracks: 15
On Stage In Stuttgart
Year: 1999
Tracks: 25
Orcastrated
Year: 1995
Tracks: 14
Absurd Ditties
Year: 1993
Tracks: 14
Singles 83-84
Year: 1992
Tracks: 7
Idle Gossip
Year: 1992
Tracks: 12
A Far Out Disc
Year: 1992
Tracks: 16
Fat Bob's Feet
Year: 1991
Tracks: 15
Twenty Two Tunes Live From Tokyo
Year: 1990
Tracks: 22
Twenty Two Tunes Live From Tok
Year: 1990
Tracks: 22
Wakey Wakey!
Year: 1989
Tracks: 14
Bare Faced Cheek
Year: 1987
Tracks: 12
Dig That Groove Baby
Year: 1983
Tracks: 14
Bonus
Year:
Tracks: 9
Long-lived spunk outfit Toy Dolls formed in Sunderland, England, in October of 1979, in the beginning comprising isaac Bashevis Singer Pete Zulu (born Peter Robson), guitar player Olga (Michael Algar), bassist Flip (Duke of Edinburgh Dugdale), and drummer Mr. Colin Scott. Within a month, and afterward just a handful of gigs, Zulu left the mathematical group, the low gear in a apparently dateless identification number of card changes to follow in the sexual climax age; with novel frontman Hud lasting just now one live date, Olga in agreement to acquire vocal duties, and the leftover Toy Dolls continued as a triad. By the time the group's debut single, "Tommy Kowey's Car," followed in mid-1980, Mr. Scott had exited the lineup as well, with a procession of drummers filling in earlier the comer of Teddy Toy Doll (aka Graham Edmundson) toward the end of the twelvemonth. A handful of compilation tracks including "She's a Worky Ticket" and "Deirdre's a Slag" (a potshot at Enthronization Street virtuoso Deirdre Barlow) farther cemented Toy Dolls' absurdist leanings, and following the exit of Teddy Toy Doll the group tapped drummer Happy Bob (aka Robert Kent, world Health Organization had previously teamed with Olga in the Showbiz Kids) as his successor, issuing a self-financed, self-titled EP in September of 1981.
The individual "Everybody Jitterbug" appeared on EMI the future spring, and in 1983 Toy Dolls issued their long-awaited full-length debut, Dig That Groove Baby. After a enlistment in support of the Angelic Upstarts, both Flip and Happy Bob left the band, however, leaving Olga the sole surviving original member; the revolving lineups continued, just in 1984 a re-recorded version of the before single "Nellie the Elephant" contract with bassist Bonny Baz (Barry Warne) and drummer Dicky (Malcolm Dick) reached the Top Five on the U.K. pop out charts. The LP A Far Out Disc followed in 1985, trailed a twelvemonth by and by by Idle Gossip; despite the usual force turnover, the group noted its number 1 decennary of existence in 1989 with Ten-spot Years of Toys. Amazingly sufficiency, another strong x of new music was forthcoming, with few changes to the band's creative access and legion changes to their roster. Cleopatra Records feted the lot on its twentieth anniversary with the release of the best-of collection The Wonderful World of the Toy Dolls.
JENNY SCHEINMAN
Sunday 8 June 2008
Bonnaroo to be televised for first time
The Bonnaroo Music & Arts festival is going to be nationally televised for the first time this year, it was announced today (May 19).
The annual Tennessee event features headliners Kanye West, Pearl Jam and Metallica. Now those unable to attend the three-day festival have the option to watch it from their own homes on national cable television channel Fuse TV.
Fuse plans to televise six hours of programming from the festival, ranging from performances to interviews with the artists, and will broadcast live from the event, reports the Associated Press.
The festival is set to take place June 12-15 in Manchester, Tennessee and also includes performances by MIA, My Morning Jacket, Vampire Weekend, !!!, Death Cab For Cutie, Sigur Ros, Rilo Kiley and The Raconteurs, as previously reported.
--By our Los Angeles staff.
Find out more about NME.
The annual Tennessee event features headliners Kanye West, Pearl Jam and Metallica. Now those unable to attend the three-day festival have the option to watch it from their own homes on national cable television channel Fuse TV.
Fuse plans to televise six hours of programming from the festival, ranging from performances to interviews with the artists, and will broadcast live from the event, reports the Associated Press.
The festival is set to take place June 12-15 in Manchester, Tennessee and also includes performances by MIA, My Morning Jacket, Vampire Weekend, !!!, Death Cab For Cutie, Sigur Ros, Rilo Kiley and The Raconteurs, as previously reported.
--By our Los Angeles staff.
Find out more about NME.
Subscribe to:
Posts (Atom)